after enrollment, the assignment to one of the two treatment groups is made by the study system.

the patient may receive a placebo tablet that looks identical to the active oral medication; this tablet is only taken at the randomisation visit and not used later.

the first treatment cycle begins following randomisation.

the patient receives instructions on how to take the oral medication and on the schedule for intravenous infusions.

the patient takes one orelabrutinib tablet containing 150 mg once daily by mouth.

the tablet is taken at the same time each day for the entire period that the study treatment is administered.

on scheduled infusion days, the patient receives an intravenous rituximab infusion at a dose of 375 mg per square meter of body‑surface area.

on the same or subsequent infusion days, the patient receives an intravenous bendamustine infusion at a dose of 90 mg per square meter of body‑surface area.

each infusion is given over the time period defined by the study protocol and is repeated in each treatment cycle.

before and after each infusion, the patient undergoes safety assessments that include blood laboratory tests, an electrocardiogram (ecg), vital‑sign measurements, and a performance‑status evaluation.

these assessments are performed at each study visit to monitor the patient’s response and any side effects.

the patient continues to receive the oral orelabrutinib tablet daily and the scheduled intravenous infusions of rituximab and bendamustine in subsequent cycles.

the number of cycles and total duration are determined by the study protocol and continue until the defined end of treatment, disease progression, or unacceptable toxicity.

after the final treatment cycle, the patient stops taking the oral medication and no further infusions are given.

a final set of clinical assessments is performed to document the outcome of the study treatment.